The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
Subscribe To Our Newsletter & Stay Updated
